#SSRIs

A recent study in the Journal of Positive Psychology links optimism to better responses to SSRI antidepressants, a cornerstone treatment for major depressive disorder. The research suggests that more optimistic individuals are likelier to improve on these medications, and that growing optimism during treatment further increases recovery chances. The findings point to new avenues for mental health care in Thailand and beyond.

In Thai society, where depression remains a hidden burden, these results are particularly relevant. Depression contributes significantly to disability, and cultural factors can hinder help-seeking and adherence to long-term treatment. SSRIs are widely prescribed by mental health professionals across the country, yet responses vary. Understanding the role of optimism could help clinicians tailor care more effectively.

A recent study published in the Journal of Positive Psychology has uncovered a striking link between optimism and the likelihood of responding positively to selective serotonin reuptake inhibitors (SSRIs), a mainstay medication for major depressive disorder. The research suggests that individuals with a more optimistic outlook are not only better positioned to benefit from these antidepressants, but that increases in optimism during treatment also significantly raise the chances of recovery—a finding with important implications for the future of mental health care in Thailand and globally (PsyPost).

A widely-prescribed antidepressant may significantly shorten lifespan—by up to six years—according to recent findings circulated by the international medical community. The claim, based on a new research review highlighted by several medical news outlets and summarized in a viral Yahoo Lifestyle article, is igniting debate among doctors, mental health professionals, and patients in Thailand and around the world over the safety and prescription practices of this common medication.

The backdrop of this news is the widespread and growing use of antidepressant drugs, especially selective serotonin reuptake inhibitors (SSRIs), which include widely-recognized names such as sertraline, fluoxetine, and paroxetine. With depression and anxiety rates rising globally—including in Thailand, where mental health awareness has increased sharply in the aftermath of the Covid-19 pandemic—these medications are standard tools for primary care doctors and psychiatrists alike [World Health Organization].

A recent review circulating in medical circles has sparked questions about whether some antidepressants might be linked to shorter life expectancy. While headlines grab attention, experts caution that the findings are complex and do not establish a direct cause-and-effect link for most patients. The discussion underscores the ongoing balance between treating depression and monitoring potential risks.

Antidepressants, especially selective serotonin reuptake inhibitors, are widely used to manage depression and anxiety. In Thailand, as awareness rises after the Covid-19 era, primary care doctors and psychiatrists increasingly rely on these medications alongside counseling and lifestyle support. Data from Thailand’s public health authorities show a growing acceptance of discussing mental health and pursuing combination treatments.